CRESCI, BARBARA
 Distribuzione geografica
Continente #
NA - Nord America 1.540
EU - Europa 646
AS - Asia 189
Totale 2.375
Nazione #
US - Stati Uniti d'America 1.534
PL - Polonia 216
IE - Irlanda 143
SE - Svezia 115
HK - Hong Kong 85
IT - Italia 62
CN - Cina 47
JO - Giordania 26
DE - Germania 24
FI - Finlandia 22
UA - Ucraina 22
RU - Federazione Russa 13
SG - Singapore 12
GB - Regno Unito 11
CH - Svizzera 7
CA - Canada 6
TR - Turchia 6
VN - Vietnam 6
BE - Belgio 4
ES - Italia 3
FR - Francia 3
IN - India 3
MY - Malesia 2
KR - Corea 1
MM - Myanmar 1
NL - Olanda 1
Totale 2.375
Città #
Fairfield 262
Warsaw 216
Chandler 168
Dublin 143
Ashburn 114
Cambridge 107
Seattle 106
Woodbridge 100
Wilmington 96
Houston 90
Hong Kong 50
Ann Arbor 43
Jacksonville 39
Princeton 36
Buffalo 33
Lawrence 32
Altamura 31
Boston 24
Kent 24
Beijing 19
Florence 16
Medford 16
Shanghai 16
Boardman 15
Moscow 12
San Diego 12
New York 10
Singapore 8
Bern 7
Falls Church 7
Andover 6
Dong Ket 6
Izmir 5
Brussels 4
West Jordan 4
Frankfurt Am Main 3
Glen Burnie 3
Los Angeles 3
Milan 3
Ottawa 3
Selvazzano Dentro 3
Toronto 3
Auburn Hills 2
Barcelona 2
Norwalk 2
Phoenix 2
Rome 2
Shah Alam 2
Tappahannock 2
Bremen 1
Esslingen am Neckar 1
Forest City 1
Islington 1
Kilburn 1
Laurel 1
Leawood 1
Louisville 1
Madrid 1
Mumbai 1
Naaldwijk 1
New Bedfont 1
Northridge 1
Redmond 1
Seoul 1
Sindelfingen 1
Washington 1
Yangon 1
Totale 1.930
Nome #
Fit and motivated: outcome predictors in patients starting a program for lifestyle change. 210
False and true pre-treatment predictors of weight loss in obese patients starting a program for lifestyle change. 152
Platelet-activating factor enhances production of insulin-like growth factor binding proteins in a human adenocarcinoma cell line (HEC-1A) 122
Lower and higher-potency statins on glycemic control in type 2 diabetes: A retrospective cohort study 101
Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. 94
Are psychopathological features relevant predictors of glucose control in patients with type 2 diabetes? A prospective study 84
Group versus individual cognitive-behavioral treatment for obesity: Results after 36 months 83
Diabetic microangiopathy: IGFBP control endothelial cell growth by a common mechanism in spite of their species specificity and tissue peculiarity. 82
Inflammation markers and metabolic characteristics of subjects with 1-h plasma glucose levels. 80
Failure to metformin and insulin secretagogue monotherapy: an observational cohort study. 79
Reply to Josef Finsterer “MELAS requires broad clinical and genetic work-up” 78
Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment 73
Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. 72
EFFECTS OF INSULIN AND GLUCOSE ON THE GROWTH AND THE RELEASE OF EXTRACELLULAR-MATRIX COMPONENTS BY BOVINE BONE ENDOTHELIAL-CELLS 70
Glomerular hyperfiltration and metabolic syndrome: results from the FIrenze-BAgno A Ripoli (FIBAR) Study 70
Insulin resistance and obesity affect monocyte-derived dendritic cell phenotype and function 66
Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. 64
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials 64
All roads bring to Rome: a different way for predicting success in the therapy of obesity through psychological features 63
Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. 62
National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study. 60
Metabolic surgery for the treatment of type 2 diabetes: A network meta-analysis of randomized controlled trials 58
Motivational readiness to change in lifestyle modification programs 56
Hyperparathyroidim: Is It Really the Major Factor Affecting Glucose Tolerance in Uremia. 54
Obesity as a risk factor for hospitalization in COronaVirus Disease-19 (COVID-19) patients: Analysis of the Tuscany regional database 54
Doses of insulin and its analogues and cancer occurence in insulin-treated type 2 diabetic patients. 49
Inflammation markers and metabolic characteristic of subjects with one-hour plasma glucose levels 43
MANAGEMENT OF HYPERGLICEMIA IN TYPE 2 DIABETES: A CONSENSUS ALGORITHM FOR THE INITIATION AND ADJUSTMENT OF THERAPY: A CONSENSUS STATEMENT FROM THE AMERICAN DIABETES ASSOCIATION AND THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES 41
Efficacy and effects of bariatric surgery in the treatment of obesity: Network meta-analysis of randomized controlled trials 38
Body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR) e waist body mass index (wBMI): Which is better? 34
Online group lifestyle modification programs for obesity during the COVID-19 pandemic: The EDucation ONline (EDON) retrospective study 32
Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS) 28
Effectiveness of Low Carbohydrate diets for long-term weight loss in obese individuals: a meta-analysis of randomized controlled trials 27
Obesity therapy: How and why? 18
Factor analysis as a tool to explore the heterogeneity of type 2 diabetes: A feasibility study 18
Effectiveness of intermittent fasting for weight loss in individuals with obesity: A meta-analysis of randomized controlled trials 17
Totale 2.396
Categoria #
all - tutte 7.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.688


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020522 41 39 7 43 65 69 60 64 56 36 33 9
2020/2021287 23 31 42 21 14 20 6 23 28 34 26 19
2021/2022238 5 15 19 7 14 11 5 12 13 16 49 72
2022/2023654 60 122 28 56 40 118 79 20 101 3 15 12
2023/2024265 12 33 40 8 12 33 16 56 3 16 28 8
2024/202520 20 0 0 0 0 0 0 0 0 0 0 0
Totale 2.396